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Hamid R Noori* and Rainer SpanagelIntroduction of new drugs and novel therapeutic solu-
tions is a long and costly process (Myers and Baker
2001; DiMasi et al., 2003). Traditionally, pharmacologists
strive to optimize and accelerate this process by develop-
ing new in vivo and in vitro investigation strategies.
However, the last decades have been witnessing the
rise of alternative research models, the so-called in silico
approaches, using computational environments as their
experimental laboratories.
Imitating the common biological terms in vivo and
in vitro, the term in silico refers to performing experi-
ments using computers. Although the historical origin of
this term is not clear, it is safe to assume that silico is a
reference to the chemical element Silicon (Si), a key
component of computer chips.
The majority of the in silico methods are primarily
used in parallel with the generation of in vivo and
in vitro data for accurate modeling and validation of a
wide range of applications from the ligand design and
optimization to the characterization of fundamental
pharmacological properties of molecules such as ab-
sorption, distribution, metabolism, excretion and tox-
icity (Ekins et al., 2007). The diversity of the developed
mathematical and biophysical models in this field
resembles the manifoldness of the pharmacological pro-
blems uniquely.
While the seminal work of Hansch and Fujita (1964)
on the statistical relationships between the molecular
structure and a specific chemical or biological property
(Quantitative structure-activity relationships) initiated
the application of modern data mining and statistical
techniques such as the virtual ligand screening (Oprea
and Matter, 2004) and the virtual affinity profiling
(O'Connor and Roth, 2005; Paolini et al., 2006), bio-
physical (Jones and Woodhall, 2005; Graupner and
Gutkin, 2009) and neurochemical network models* Correspondence: hamid.noori@zi-mannheim.de
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mainly apply deterministic dynamical systems to identify
drug-induced alterations of electrophysiological and/or
neurochemical network characteristics.
In light of the rapid progress of in silico approaches,
it could be expected that biomedical investigations in
virtual reality ultimately lead to rigorous changes in the
pharmaceutical research landscape by optimizing the
drug development process, reducing the number of ani-
mal experiments and smoothing the path to persona-
lized medicine.
Despite the increasing interest in this field of research,
publication platforms with dedicated agenda to in silico
pharmacology are missing. With the launch of our jour-
nal, we aim to fill this gap and provide a forum for inter-
disciplinary research articles that specifically address
computational approaches in drug-design and multi-
scale analysis of bioactive substances from the cellular
up to behavioral level.
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